| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 78 | 2024 | 1800 | 9.840 |
Why?
|
| Atherosclerosis | 68 | 2024 | 828 | 9.240 |
Why?
|
| Troponin T | 46 | 2024 | 245 | 5.890 |
Why?
|
| Heart Failure | 51 | 2024 | 2125 | 4.950 |
Why?
|
| Coronary Artery Disease | 31 | 2024 | 743 | 4.730 |
Why?
|
| Natriuretic Peptide, Brain | 29 | 2024 | 276 | 4.390 |
Why?
|
| Carotid Intima-Media Thickness | 20 | 2023 | 72 | 4.380 |
Why?
|
| Biomarkers | 86 | 2024 | 2926 | 3.820 |
Why?
|
| Risk Assessment | 65 | 2024 | 3289 | 3.690 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 33 | 2024 | 713 | 3.560 |
Why?
|
| Coronary Disease | 24 | 2023 | 632 | 3.440 |
Why?
|
| Plaque, Atherosclerotic | 16 | 2023 | 119 | 3.380 |
Why?
|
| Hypertension | 22 | 2024 | 1264 | 3.260 |
Why?
|
| Risk Factors | 131 | 2024 | 9718 | 3.240 |
Why?
|
| Peptide Fragments | 25 | 2024 | 744 | 2.850 |
Why?
|
| Carotid Artery Diseases | 12 | 2020 | 147 | 2.830 |
Why?
|
| Cholesterol, LDL | 23 | 2024 | 548 | 2.600 |
Why?
|
| Diabetes Mellitus | 18 | 2024 | 837 | 2.420 |
Why?
|
| Myocardial Infarction | 19 | 2024 | 996 | 2.370 |
Why?
|
| Blood Pressure | 19 | 2024 | 1300 | 2.240 |
Why?
|
| Dyslipidemias | 10 | 2021 | 225 | 2.230 |
Why?
|
| Humans | 285 | 2024 | 121793 | 2.070 |
Why?
|
| Proprotein Convertase 9 | 7 | 2024 | 67 | 2.050 |
Why?
|
| Carotid Arteries | 7 | 2022 | 151 | 2.000 |
Why?
|
| Vascular Stiffness | 7 | 2022 | 75 | 2.000 |
Why?
|
| Hyperlipoproteinemia Type II | 5 | 2021 | 84 | 1.970 |
Why?
|
| Peripheral Arterial Disease | 15 | 2023 | 268 | 1.840 |
Why?
|
| Hypolipidemic Agents | 7 | 2024 | 176 | 1.780 |
Why?
|
| Middle Aged | 147 | 2024 | 25516 | 1.760 |
Why?
|
| Cholesterol | 14 | 2022 | 507 | 1.600 |
Why?
|
| Anticholesteremic Agents | 6 | 2024 | 230 | 1.570 |
Why?
|
| Aged | 112 | 2024 | 18732 | 1.490 |
Why?
|
| C-Reactive Protein | 19 | 2024 | 402 | 1.470 |
Why?
|
| Primary Prevention | 7 | 2024 | 162 | 1.470 |
Why?
|
| Male | 166 | 2024 | 59243 | 1.400 |
Why?
|
| Cholesterol, HDL | 6 | 2024 | 336 | 1.390 |
Why?
|
| Stroke | 15 | 2024 | 956 | 1.360 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 9 | 2019 | 87 | 1.310 |
Why?
|
| United States | 72 | 2024 | 10413 | 1.290 |
Why?
|
| Acute Coronary Syndrome | 6 | 2021 | 198 | 1.280 |
Why?
|
| Vascular Calcification | 4 | 2024 | 52 | 1.230 |
Why?
|
| Female | 159 | 2024 | 64573 | 1.230 |
Why?
|
| Carotid Artery, Common | 5 | 2012 | 73 | 1.180 |
Why?
|
| Galectin 3 | 4 | 2024 | 31 | 1.180 |
Why?
|
| Heart Diseases | 5 | 2019 | 479 | 1.180 |
Why?
|
| Secondary Prevention | 3 | 2024 | 208 | 1.170 |
Why?
|
| Obesity | 16 | 2023 | 1938 | 1.140 |
Why?
|
| Prospective Studies | 48 | 2024 | 5960 | 1.140 |
Why?
|
| Preventive Health Services | 2 | 2018 | 54 | 1.140 |
Why?
|
| Incidence | 34 | 2024 | 2962 | 1.060 |
Why?
|
| Prognosis | 32 | 2024 | 4438 | 1.030 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 622 | 0.980 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 216 | 0.960 |
Why?
|
| Echocardiography | 7 | 2024 | 1068 | 0.950 |
Why?
|
| Carotid Artery, Internal | 3 | 2015 | 66 | 0.930 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2019 | 35 | 0.900 |
Why?
|
| Carotid Stenosis | 5 | 2021 | 132 | 0.890 |
Why?
|
| Brain Ischemia | 5 | 2023 | 258 | 0.850 |
Why?
|
| Cardiology | 9 | 2023 | 470 | 0.850 |
Why?
|
| Metabolic Syndrome | 6 | 2024 | 319 | 0.850 |
Why?
|
| Coronary Vessels | 5 | 2021 | 525 | 0.840 |
Why?
|
| Ultrasonography | 6 | 2015 | 945 | 0.820 |
Why?
|
| Practice Guidelines as Topic | 12 | 2019 | 1244 | 0.820 |
Why?
|
| Troponin | 4 | 2024 | 71 | 0.820 |
Why?
|
| Calcium | 6 | 2024 | 1096 | 0.800 |
Why?
|
| Inflammation | 7 | 2022 | 1393 | 0.800 |
Why?
|
| Tunica Intima | 3 | 2011 | 59 | 0.800 |
Why?
|
| Clinical Trials as Topic | 10 | 2024 | 1078 | 0.770 |
Why?
|
| Body Mass Index | 14 | 2023 | 1403 | 0.760 |
Why?
|
| Chromosomes, Human, Pair 9 | 5 | 2012 | 106 | 0.750 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 354 | 0.750 |
Why?
|
| Antihypertensive Agents | 7 | 2024 | 391 | 0.740 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2023 | 195 | 0.740 |
Why?
|
| Dicarboxylic Acids | 1 | 2021 | 34 | 0.740 |
Why?
|
| Lipoprotein(a) | 7 | 2022 | 113 | 0.740 |
Why?
|
| Platelet Aggregation Inhibitors | 7 | 2021 | 256 | 0.730 |
Why?
|
| Vascular Diseases | 3 | 2022 | 161 | 0.730 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2021 | 223 | 0.720 |
Why?
|
| Lipids | 9 | 2023 | 504 | 0.720 |
Why?
|
| American Heart Association | 7 | 2023 | 292 | 0.720 |
Why?
|
| Predictive Value of Tests | 17 | 2024 | 2074 | 0.700 |
Why?
|
| Protein Precursors | 4 | 2021 | 150 | 0.680 |
Why?
|
| Hospitalization | 13 | 2024 | 1726 | 0.680 |
Why?
|
| Cognition Disorders | 2 | 2021 | 548 | 0.680 |
Why?
|
| Troponin I | 5 | 2024 | 98 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2023 | 3441 | 0.660 |
Why?
|
| General Practitioners | 1 | 2019 | 17 | 0.660 |
Why?
|
| Hyperlipidemias | 2 | 2015 | 171 | 0.650 |
Why?
|
| Heterozygote | 1 | 2021 | 679 | 0.640 |
Why?
|
| Fatty Acids | 1 | 2021 | 338 | 0.640 |
Why?
|
| Population Surveillance | 2 | 2021 | 369 | 0.640 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2022 | 713 | 0.630 |
Why?
|
| Time Factors | 26 | 2024 | 6168 | 0.620 |
Why?
|
| Adult | 51 | 2024 | 28549 | 0.620 |
Why?
|
| Cohort Studies | 28 | 2023 | 4623 | 0.600 |
Why?
|
| Blood Pressure Determination | 2 | 2016 | 105 | 0.590 |
Why?
|
| Phospholipases A | 5 | 2014 | 39 | 0.590 |
Why?
|
| Myocardium | 4 | 2019 | 983 | 0.590 |
Why?
|
| Education | 1 | 2018 | 105 | 0.590 |
Why?
|
| Dementia | 2 | 2024 | 440 | 0.570 |
Why?
|
| Reproducibility of Results | 14 | 2022 | 2792 | 0.570 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2021 | 68 | 0.560 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2016 | 58 | 0.560 |
Why?
|
| Coronary Artery Bypass | 10 | 2013 | 485 | 0.550 |
Why?
|
| Thrombosis | 1 | 2021 | 516 | 0.540 |
Why?
|
| Health Status Disparities | 2 | 2024 | 207 | 0.540 |
Why?
|
| Women's Health | 1 | 2017 | 127 | 0.540 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2023 | 1154 | 0.520 |
Why?
|
| Aged, 80 and over | 26 | 2024 | 6275 | 0.520 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 353 | 0.510 |
Why?
|
| Image Enhancement | 1 | 2016 | 163 | 0.510 |
Why?
|
| Disease Management | 3 | 2017 | 511 | 0.500 |
Why?
|
| Hypoxia | 2 | 2023 | 246 | 0.490 |
Why?
|
| Sensitivity and Specificity | 11 | 2019 | 2009 | 0.490 |
Why?
|
| Postprandial Period | 1 | 2015 | 75 | 0.490 |
Why?
|
| Triglycerides | 8 | 2022 | 547 | 0.490 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2015 | 50 | 0.490 |
Why?
|
| Proportional Hazards Models | 16 | 2022 | 1269 | 0.480 |
Why?
|
| Follow-Up Studies | 23 | 2024 | 4953 | 0.480 |
Why?
|
| Oligonucleotides | 1 | 2015 | 88 | 0.470 |
Why?
|
| Hypercholesterolemia | 5 | 2021 | 225 | 0.470 |
Why?
|
| Football | 5 | 2014 | 29 | 0.470 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 74 | 0.470 |
Why?
|
| Tunica Media | 2 | 2011 | 13 | 0.460 |
Why?
|
| Leg | 5 | 2023 | 154 | 0.460 |
Why?
|
| Aspirin | 5 | 2021 | 221 | 0.460 |
Why?
|
| Ankle Brachial Index | 6 | 2022 | 37 | 0.450 |
Why?
|
| Dietary Fats | 1 | 2015 | 273 | 0.440 |
Why?
|
| Prevalence | 14 | 2024 | 2322 | 0.440 |
Why?
|
| Income | 2 | 2024 | 132 | 0.440 |
Why?
|
| Treatment Outcome | 27 | 2023 | 12003 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2013 | 2511 | 0.420 |
Why?
|
| Clinical Competence | 2 | 2019 | 976 | 0.420 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2023 | 75 | 0.410 |
Why?
|
| Mortality | 4 | 2024 | 223 | 0.410 |
Why?
|
| Platelet Aggregation | 2 | 2011 | 120 | 0.410 |
Why?
|
| Pulse Wave Analysis | 4 | 2022 | 47 | 0.410 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2011 | 89 | 0.400 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2012 | 25 | 0.400 |
Why?
|
| Goals | 4 | 2020 | 126 | 0.400 |
Why?
|
| Ultrasonography, Doppler | 3 | 2014 | 197 | 0.390 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 480 | 0.370 |
Why?
|
| Peroxidase | 3 | 2008 | 61 | 0.370 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 126 | 0.370 |
Why?
|
| Prediabetic State | 2 | 2024 | 54 | 0.370 |
Why?
|
| Vasa Vasorum | 1 | 2010 | 3 | 0.370 |
Why?
|
| Biological Transport | 2 | 2024 | 347 | 0.370 |
Why?
|
| Retirement | 4 | 2014 | 18 | 0.370 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 3 | 2021 | 44 | 0.360 |
Why?
|
| Residence Characteristics | 6 | 2024 | 247 | 0.360 |
Why?
|
| Machine Learning | 2 | 2024 | 213 | 0.350 |
Why?
|
| HIV Infections | 2 | 2020 | 1842 | 0.350 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 125 | 0.350 |
Why?
|
| Veterans | 5 | 2023 | 1715 | 0.350 |
Why?
|
| Health Status Indicators | 1 | 2010 | 117 | 0.350 |
Why?
|
| Ezetimibe | 5 | 2019 | 95 | 0.350 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 3289 | 0.340 |
Why?
|
| Exercise | 4 | 2021 | 745 | 0.340 |
Why?
|
| Hypertriglyceridemia | 3 | 2022 | 100 | 0.340 |
Why?
|
| Cause of Death | 4 | 2024 | 454 | 0.340 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2024 | 37 | 0.340 |
Why?
|
| Retrospective Studies | 25 | 2024 | 15794 | 0.340 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 125 | 0.330 |
Why?
|
| Severity of Illness Index | 13 | 2021 | 2809 | 0.320 |
Why?
|
| ROC Curve | 5 | 2012 | 544 | 0.320 |
Why?
|
| Platelet Activation | 1 | 2009 | 70 | 0.320 |
Why?
|
| Life Expectancy | 1 | 2009 | 49 | 0.320 |
Why?
|
| Healthy Lifestyle | 2 | 2020 | 28 | 0.320 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2022 | 107 | 0.310 |
Why?
|
| Drug Costs | 2 | 2019 | 61 | 0.310 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 220 | 0.310 |
Why?
|
| Guideline Adherence | 8 | 2019 | 375 | 0.310 |
Why?
|
| Nutrition Surveys | 3 | 2024 | 278 | 0.310 |
Why?
|
| Lipoproteins, HDL | 2 | 2024 | 92 | 0.310 |
Why?
|
| Odds Ratio | 12 | 2019 | 1189 | 0.300 |
Why?
|
| Registries | 6 | 2018 | 1318 | 0.300 |
Why?
|
| Lipoproteins | 4 | 2022 | 175 | 0.300 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 26 | 0.300 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2018 | 710 | 0.300 |
Why?
|
| Eligibility Determination | 2 | 2019 | 39 | 0.300 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 37 | 0.300 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 500 | 0.300 |
Why?
|
| Sex Factors | 6 | 2017 | 1231 | 0.290 |
Why?
|
| Double-Blind Method | 8 | 2021 | 1561 | 0.290 |
Why?
|
| Comorbidity | 7 | 2024 | 1484 | 0.290 |
Why?
|
| Femoral Artery | 4 | 2023 | 190 | 0.280 |
Why?
|
| Ischemia | 2 | 2020 | 344 | 0.280 |
Why?
|
| Intermittent Claudication | 3 | 2023 | 54 | 0.280 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 233 | 0.280 |
Why?
|
| Galectins | 3 | 2022 | 18 | 0.270 |
Why?
|
| Stroke Volume | 4 | 2024 | 448 | 0.270 |
Why?
|
| Cognition | 3 | 2024 | 723 | 0.270 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 180 | 0.270 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2021 | 224 | 0.270 |
Why?
|
| Apolipoprotein A-I | 2 | 2011 | 77 | 0.260 |
Why?
|
| Heart Ventricles | 3 | 2021 | 767 | 0.260 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 428 | 0.260 |
Why?
|
| Solvents | 1 | 2005 | 39 | 0.250 |
Why?
|
| Heart Septum | 1 | 2005 | 57 | 0.250 |
Why?
|
| United States Department of Veterans Affairs | 6 | 2021 | 645 | 0.250 |
Why?
|
| Heart-Assist Devices | 2 | 2024 | 1022 | 0.240 |
Why?
|
| Calcinosis | 3 | 2014 | 167 | 0.240 |
Why?
|
| Echocardiography, Stress | 2 | 2020 | 16 | 0.240 |
Why?
|
| Protective Factors | 3 | 2021 | 82 | 0.240 |
Why?
|
| Clinical Decision-Making | 4 | 2021 | 266 | 0.240 |
Why?
|
| Waist Circumference | 2 | 2014 | 83 | 0.230 |
Why?
|
| Renin-Angiotensin System | 2 | 2024 | 95 | 0.230 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2024 | 28 | 0.230 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 172 | 0.230 |
Why?
|
| Ethanol | 1 | 2005 | 159 | 0.230 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2024 | 51 | 0.230 |
Why?
|
| Dioxygenases | 1 | 2024 | 46 | 0.230 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2005 | 152 | 0.220 |
Why?
|
| Genome-Wide Association Study | 6 | 2013 | 1587 | 0.220 |
Why?
|
| Young Adult | 7 | 2024 | 8676 | 0.220 |
Why?
|
| Cardiologists | 1 | 2023 | 20 | 0.220 |
Why?
|
| Life Style | 4 | 2021 | 342 | 0.220 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 94 | 0.220 |
Why?
|
| Confidence Intervals | 4 | 2017 | 274 | 0.220 |
Why?
|
| Thromboembolism | 1 | 2004 | 84 | 0.220 |
Why?
|
| Phenotype | 8 | 2024 | 4200 | 0.220 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 94 | 0.220 |
Why?
|
| Simvastatin | 4 | 2015 | 75 | 0.210 |
Why?
|
| Heart | 3 | 2024 | 725 | 0.210 |
Why?
|
| Texas | 10 | 2024 | 3431 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2024 | 98 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2024 | 1022 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 1021 | 0.210 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 412 | 0.200 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2022 | 11 | 0.200 |
Why?
|
| Hypotension | 1 | 2024 | 176 | 0.200 |
Why?
|
| Blood Volume | 2 | 2020 | 79 | 0.200 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 507 | 0.200 |
Why?
|
| Circadian Rhythm | 1 | 2024 | 266 | 0.200 |
Why?
|
| Thrombolytic Therapy | 1 | 2004 | 203 | 0.200 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 80 | 0.200 |
Why?
|
| Suicide | 1 | 2024 | 170 | 0.200 |
Why?
|
| Forecasting | 2 | 2018 | 349 | 0.200 |
Why?
|
| Age Factors | 7 | 2020 | 2757 | 0.200 |
Why?
|
| Surveys and Questionnaires | 6 | 2019 | 3601 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2004 | 180 | 0.200 |
Why?
|
| Thigh | 3 | 2022 | 49 | 0.190 |
Why?
|
| Linear Models | 6 | 2017 | 650 | 0.190 |
Why?
|
| Obesity, Metabolically Benign | 1 | 2021 | 3 | 0.190 |
Why?
|
| Hospital Mortality | 6 | 2024 | 995 | 0.190 |
Why?
|
| Pancreatitis | 1 | 2022 | 127 | 0.190 |
Why?
|
| Contrast Media | 4 | 2019 | 464 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2023 | 2997 | 0.190 |
Why?
|
| Muscle, Skeletal | 4 | 2023 | 928 | 0.190 |
Why?
|
| Military Medicine | 1 | 2021 | 46 | 0.190 |
Why?
|
| Preoperative Care | 4 | 2012 | 350 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 158 | 0.180 |
Why?
|
| Receptors, LDL | 1 | 2021 | 90 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 815 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 17 | 0.180 |
Why?
|
| Fish Oils | 1 | 2021 | 82 | 0.180 |
Why?
|
| Albuminuria | 2 | 2022 | 91 | 0.180 |
Why?
|
| Apolipoproteins B | 2 | 2019 | 131 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 558 | 0.180 |
Why?
|
| Artificial Intelligence | 2 | 2020 | 231 | 0.180 |
Why?
|
| Patient Selection | 3 | 2019 | 676 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2022 | 148 | 0.180 |
Why?
|
| Data Collection | 1 | 2022 | 383 | 0.180 |
Why?
|
| Consensus | 2 | 2021 | 604 | 0.170 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 6 | 0.170 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 211 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2020 | 61 | 0.170 |
Why?
|
| Perfusion | 2 | 2023 | 197 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 28 | 0.170 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 51 | 0.170 |
Why?
|
| Microvessels | 1 | 2020 | 56 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 992 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2020 | 65 | 0.170 |
Why?
|
| Drug Prescriptions | 3 | 2018 | 215 | 0.170 |
Why?
|
| Retinal Vessels | 1 | 2020 | 74 | 0.170 |
Why?
|
| India | 1 | 2020 | 218 | 0.170 |
Why?
|
| Risk | 5 | 2014 | 724 | 0.160 |
Why?
|
| P-Selectin | 2 | 2010 | 77 | 0.160 |
Why?
|
| Logistic Models | 9 | 2016 | 1725 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2024 | 813 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 117 | 0.160 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2018 | 16 | 0.160 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 448 | 0.160 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2019 | 92 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 146 | 0.160 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 664 | 0.160 |
Why?
|
| Renal Insufficiency | 3 | 2011 | 232 | 0.160 |
Why?
|
| Behavior Therapy | 1 | 2021 | 213 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 501 | 0.160 |
Why?
|
| Walking | 1 | 2020 | 196 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 141 | 0.160 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 638 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2012 | 210 | 0.150 |
Why?
|
| Benchmarking | 1 | 2019 | 131 | 0.150 |
Why?
|
| Exercise Therapy | 3 | 2021 | 133 | 0.150 |
Why?
|
| Treatment Failure | 2 | 2018 | 335 | 0.150 |
Why?
|
| Smoking Cessation | 1 | 2020 | 193 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 245 | 0.150 |
Why?
|
| Veterans Health | 2 | 2019 | 172 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 78 | 0.150 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 278 | 0.150 |
Why?
|
| Sick Sinus Syndrome | 1 | 2018 | 12 | 0.150 |
Why?
|
| Postoperative Complications | 5 | 2012 | 2987 | 0.150 |
Why?
|
| Endarterectomy, Carotid | 2 | 2015 | 92 | 0.150 |
Why?
|
| Smoking | 3 | 2023 | 1018 | 0.150 |
Why?
|
| Apolipoprotein C-III | 2 | 2022 | 36 | 0.150 |
Why?
|
| Inpatients | 3 | 2024 | 489 | 0.150 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 55 | 0.150 |
Why?
|
| Mammography | 1 | 2018 | 111 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 188 | 0.150 |
Why?
|
| Hypogonadism | 1 | 2021 | 249 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2019 | 290 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 354 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 4 | 2022 | 481 | 0.140 |
Why?
|
| Phospholipases A2 | 2 | 2007 | 35 | 0.140 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 140 | 0.140 |
Why?
|
| Physicians | 1 | 2023 | 582 | 0.140 |
Why?
|
| Myocardial Revascularization | 3 | 2021 | 96 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 2023 | 854 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 174 | 0.140 |
Why?
|
| Blood Proteins | 3 | 2022 | 116 | 0.130 |
Why?
|
| Femoral Vein | 1 | 2016 | 50 | 0.130 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 1272 | 0.130 |
Why?
|
| Endothelium, Vascular | 3 | 2013 | 514 | 0.130 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2016 | 17 | 0.130 |
Why?
|
| Cystatin C | 1 | 2016 | 49 | 0.130 |
Why?
|
| Testosterone | 1 | 2021 | 462 | 0.130 |
Why?
|
| Oxygen | 1 | 2019 | 548 | 0.130 |
Why?
|
| Propensity Score | 3 | 2012 | 203 | 0.130 |
Why?
|
| Metabolomics | 1 | 2019 | 388 | 0.130 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 31 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 2032 | 0.130 |
Why?
|
| Survival Rate | 5 | 2024 | 1976 | 0.130 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 170 | 0.130 |
Why?
|
| Inservice Training | 1 | 2016 | 55 | 0.130 |
Why?
|
| Endpoint Determination | 2 | 2007 | 52 | 0.130 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 1149 | 0.130 |
Why?
|
| Lower Extremity | 2 | 2022 | 178 | 0.130 |
Why?
|
| Up-Regulation | 4 | 2020 | 872 | 0.120 |
Why?
|
| Amino Acids | 1 | 2018 | 659 | 0.120 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 199 | 0.120 |
Why?
|
| Fenofibrate | 2 | 2013 | 57 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 603 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 269 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2016 | 194 | 0.120 |
Why?
|
| Internship and Residency | 2 | 2018 | 1153 | 0.120 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 131 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2019 | 383 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 1396 | 0.120 |
Why?
|
| Fibrosis | 3 | 2022 | 429 | 0.120 |
Why?
|
| Health Status | 1 | 2016 | 366 | 0.120 |
Why?
|
| Chemokine CCL5 | 2 | 2013 | 55 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2016 | 1365 | 0.120 |
Why?
|
| Heptanoic Acids | 3 | 2014 | 77 | 0.120 |
Why?
|
| Occupations | 1 | 2014 | 20 | 0.110 |
Why?
|
| Athletes | 1 | 2014 | 59 | 0.110 |
Why?
|
| Hyperglycemia | 2 | 2013 | 220 | 0.110 |
Why?
|
| Liver | 1 | 2021 | 1855 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 60 | 0.110 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 227 | 0.110 |
Why?
|
| Acetates | 1 | 2014 | 72 | 0.110 |
Why?
|
| Ceruloplasmin | 1 | 2013 | 13 | 0.110 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2009 | 425 | 0.110 |
Why?
|
| Cardiovascular Agents | 2 | 2024 | 86 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2014 | 52 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2016 | 329 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1227 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 555 | 0.110 |
Why?
|
| Brain Infarction | 1 | 2013 | 30 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2015 | 701 | 0.110 |
Why?
|
| Neck | 1 | 2014 | 134 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1101 | 0.110 |
Why?
|
| Diet Therapy | 1 | 2013 | 39 | 0.110 |
Why?
|
| Pyrroles | 3 | 2014 | 177 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 611 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 54 | 0.100 |
Why?
|
| Adenosine Diphosphate | 2 | 2011 | 58 | 0.100 |
Why?
|
| Algorithms | 4 | 2016 | 1569 | 0.100 |
Why?
|
| Curriculum | 1 | 2018 | 715 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 182 | 0.100 |
Why?
|
| Arachidonic Acid | 2 | 2011 | 69 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 570 | 0.100 |
Why?
|
| Piperazines | 1 | 2014 | 226 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 528 | 0.100 |
Why?
|
| Death | 1 | 2012 | 71 | 0.100 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2012 | 23 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2024 | 392 | 0.100 |
Why?
|
| Heart Valves | 2 | 2010 | 52 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2478 | 0.100 |
Why?
|
| Lipoproteins, LDL | 1 | 2012 | 114 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 264 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 676 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2012 | 309 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 106 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2011 | 58 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 491 | 0.090 |
Why?
|
| Platelet Function Tests | 1 | 2011 | 38 | 0.090 |
Why?
|
| Muscles | 1 | 2011 | 289 | 0.090 |
Why?
|
| Vasodilator Agents | 2 | 2022 | 203 | 0.090 |
Why?
|
| Pravastatin | 2 | 2008 | 23 | 0.090 |
Why?
|
| Mutation | 1 | 2004 | 5773 | 0.090 |
Why?
|
| Reference Values | 4 | 2017 | 693 | 0.090 |
Why?
|
| Vasculitis | 1 | 2011 | 49 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2022 | 988 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2010 | 1100 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 178 | 0.090 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2020 | 51 | 0.090 |
Why?
|
| Drug Monitoring | 2 | 2021 | 158 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2012 | 306 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2016 | 3132 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 65 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 133 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 462 | 0.080 |
Why?
|
| Apolipoproteins A | 1 | 2009 | 44 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 1685 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2012 | 740 | 0.080 |
Why?
|
| Weight Loss | 2 | 2021 | 360 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 171 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 266 | 0.080 |
Why?
|
| Niacin | 3 | 2013 | 57 | 0.080 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2021 | 21 | 0.080 |
Why?
|
| Epinephrine | 1 | 2009 | 174 | 0.080 |
Why?
|
| Adolescent | 5 | 2024 | 18773 | 0.080 |
Why?
|
| Collagen | 1 | 2009 | 312 | 0.070 |
Why?
|
| Aging | 3 | 2022 | 1164 | 0.070 |
Why?
|
| DNA | 1 | 2013 | 1606 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 968 | 0.070 |
Why?
|
| Mass Screening | 2 | 2014 | 779 | 0.070 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2008 | 366 | 0.070 |
Why?
|
| Netherlands | 2 | 2020 | 36 | 0.070 |
Why?
|
| Acute Disease | 2 | 2022 | 1088 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2007 | 78 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 813 | 0.070 |
Why?
|
| Gadolinium DTPA | 2 | 2019 | 48 | 0.070 |
Why?
|
| Patient Discharge | 2 | 2022 | 487 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2007 | 127 | 0.070 |
Why?
|
| Genotype | 4 | 2013 | 2483 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2024 | 1155 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 103 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2021 | 964 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 83 | 0.060 |
Why?
|
| Defibrillators, Implantable | 2 | 2024 | 191 | 0.060 |
Why?
|
| Mississippi | 1 | 2024 | 30 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2005 | 172 | 0.060 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2024 | 13 | 0.060 |
Why?
|
| Massachusetts | 1 | 2024 | 121 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 580 | 0.060 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 27 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2024 | 67 | 0.060 |
Why?
|
| Dyspnea | 1 | 2005 | 149 | 0.060 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 10 | 0.060 |
Why?
|
| Particle Size | 1 | 2024 | 116 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 800 | 0.060 |
Why?
|
| Angioplasty | 1 | 2004 | 85 | 0.060 |
Why?
|
| Anthropometry | 2 | 2014 | 187 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 278 | 0.060 |
Why?
|
| United Kingdom | 1 | 2024 | 190 | 0.060 |
Why?
|
| Mitral Valve | 1 | 2005 | 246 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 475 | 0.050 |
Why?
|
| Interleukin-18 | 1 | 2023 | 60 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 645 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2003 | 51 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2003 | 58 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 121 | 0.050 |
Why?
|
| Asymptomatic Diseases | 2 | 2014 | 77 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 128 | 0.050 |
Why?
|
| Quality of Life | 2 | 2022 | 1898 | 0.050 |
Why?
|
| Internationality | 1 | 2023 | 129 | 0.050 |
Why?
|
| Chest Pain | 1 | 2003 | 125 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 577 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2002 | 67 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 175 | 0.050 |
Why?
|
| Brachial Artery | 1 | 2022 | 38 | 0.050 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 12 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 55 | 0.050 |
Why?
|
| Thiazoles | 1 | 2002 | 96 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 293 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2024 | 233 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 250 | 0.050 |
Why?
|
| Coronary Angiography | 2 | 2014 | 417 | 0.050 |
Why?
|
| United States Department of Defense | 1 | 2021 | 10 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 247 | 0.050 |
Why?
|
| Alleles | 3 | 2011 | 1585 | 0.050 |
Why?
|
| Ultrasonics | 1 | 2020 | 36 | 0.050 |
Why?
|
| Metformin | 1 | 2002 | 144 | 0.050 |
Why?
|
| Weight Reduction Programs | 1 | 2021 | 39 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 860 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2012 | 701 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 396 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 117 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1110 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2021 | 94 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 89 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2013 | 446 | 0.040 |
Why?
|
| Motor Activity | 1 | 2002 | 494 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 306 | 0.040 |
Why?
|
| Exercise Test | 1 | 2020 | 245 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2002 | 454 | 0.040 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 258 | 0.040 |
Why?
|
| Genomics | 1 | 2007 | 1467 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 42 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 416 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 668 | 0.040 |
Why?
|
| Models, Economic | 1 | 2019 | 51 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2021 | 163 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 297 | 0.040 |
Why?
|
| Recurrence | 2 | 2013 | 1408 | 0.040 |
Why?
|
| Bone Density | 1 | 2021 | 305 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 232 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2021 | 330 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 261 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 353 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 847 | 0.040 |
Why?
|
| Overweight | 1 | 2020 | 307 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 364 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 421 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2021 | 452 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 728 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 156 | 0.040 |
Why?
|
| Walk Test | 1 | 2016 | 23 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 160 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 25 | 0.030 |
Why?
|
| Hyperemia | 1 | 2016 | 25 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2014 | 1463 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2015 | 59 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 589 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 913 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2016 | 157 | 0.030 |
Why?
|
| Independent Living | 1 | 2015 | 65 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 1095 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 70 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2014 | 2 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 15 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2014 | 79 | 0.030 |
Why?
|
| Keto Acids | 1 | 2014 | 55 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2014 | 51 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 232 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 77 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 808 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2013 | 39 | 0.030 |
Why?
|
| Exome | 1 | 2018 | 1034 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 101 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 83 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 58 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2012 | 30 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2012 | 28 | 0.030 |
Why?
|
| Heart Injuries | 1 | 2012 | 46 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 26 | 0.030 |
Why?
|
| Renal Dialysis | 2 | 2010 | 842 | 0.030 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 14 | 0.020 |
Why?
|
| HapMap Project | 1 | 2011 | 12 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2012 | 41 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 2012 | 53 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 110 | 0.020 |
Why?
|
| Normal Distribution | 1 | 2011 | 17 | 0.020 |
Why?
|
| Automation | 1 | 2011 | 59 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 583 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 45 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 203 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 328 | 0.020 |
Why?
|
| Family Practice | 1 | 2011 | 90 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2011 | 24 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 237 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 2011 | 45 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 212 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1710 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 282 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 87 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 304 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 507 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2011 | 257 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 744 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 147 | 0.020 |
Why?
|
| Health Services Research | 1 | 2011 | 185 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3075 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 93 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 169 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 332 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2016 | 744 | 0.020 |
Why?
|
| Angioplasty, Balloon | 1 | 2011 | 161 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 393 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 50 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 325 | 0.020 |
Why?
|
| Endocrinology | 1 | 2011 | 139 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 234 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2012 | 840 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 477 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2010 | 196 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2010 | 327 | 0.020 |
Why?
|
| Heart Valve Diseases | 1 | 2007 | 167 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 233 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 1255 | 0.010 |
Why?
|
| Stents | 1 | 2011 | 866 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 18 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2003 | 54 | 0.010 |
Why?
|
| Animals | 1 | 2005 | 33870 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 2003 | 33 | 0.010 |
Why?
|
| Length of Stay | 1 | 2009 | 1271 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 222 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 318 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 1984 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2941 | 0.010 |
Why?
|
| Neoplasms | 1 | 2012 | 2697 | 0.010 |
Why?
|